Intersect ENT, Inc. (XENT)
| Market Cap | 901.79M |
| Revenue (ttm) | 104.31M |
| Net Income (ttm) | -88.68M |
| Shares Out | 33.46M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 156,951 |
| Open | 27.07 |
| Previous Close | 27.01 |
| Day's Range | 26.92 - 27.10 |
| 52-Week Range | 15.92 - 28.17 |
| Beta | 1.52 |
| Analysts | Buy |
| Price Target | 28.25 (+4.8%) |
| Earnings Date | Nov 1, 2021 |
About XENT
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL and PROPEL Mini, which are steroid releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a steril...
Financial Performance
In 2020, Intersect ENT's revenue was $80.55 million, a decrease of -26.19% compared to the previous year's $109.14 million. Losses were -$72.32 million, 68.2% more than in 2019.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for Intersect ENT stock is "Buy." The 12-month stock price forecast is 28.25, which is an increase of 4.82% from the latest price.
News
Intersect ENT's (XENT) Sell-Off on Track Amid COVID Woes
Amid industry-wide concerns of deferral of elective procedures, Intersect ENT's (XENT) plans to consolidate with an industry behemoth like Medtronic seems a strategically aligned survival plan.
Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track
An increase in Intersect ENT's (XENT) operating costs puts pressure on its Q3 bottom line.
Intersect ENT (XENT) Reports Q3 Loss, Lags Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -14.29% and -17.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT Reports Third Quarter 2021 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Third Quarter 2021 Financial Results
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
MENLO PARK, Calif.--(BUSINESS WIRE)--First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
Analysts Estimate Intersect ENT (XENT) to Report a Decline in Earnings: What to Look Out for
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intersect ENT, Inc. - XENT
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Actio...
Intersect ENT's (XENT) Sell Off Plan Strategic Amid Pandemic
Intersect ENT's (XENT) top-line growth from the PROPEL family of products and SINUVA continues to be challenged by seasonal variations in the volume of sinus surgery procedures.
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Intersect ENT, Inc.
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Intersect ENT, Inc. (NASDAQ: XENT) and its board of directors concerning the proposed acqui...
Intersect ENT (XENT) Q2 Loss Wider Than Expected, Revenues Top
Intersect ENT's (XENT) second-quarter revenues improved year over year on increased PROPEL and SINUVA sales.
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intersect ENT, Inc.
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Intersect ENT, Inc. ("Intersect" or the ...
Why Intersect ENT Shot 12% Higher on Friday
It's official: A big peer is buying out the specialty medical device maker.
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Intersect ENT, Inc. (NASDAQ: XENT) to Medtronic plc for $28.25 per share is fair to I...
Shareholder Alert: Ademi LLP investigates whether Intersect ENT, Inc. has obtained a Fair Price in its transaction wi...
MILWAUKEE, Aug. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating Intersect ENT (NASDAQ: XENT) for possible breaches of fiduciary duty and other violations of law in its transaction with Medtronic. Cli...
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
Intersect ENT (XENT) delivered earnings and revenue surprises of -16.67% and 0.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Medtronic plc (NYSE:MDT) has agreed to acquire Intersect ENT Inc (NASDAQ:XENT) for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion. Medtronic's ac...
Intersect ENT Reports Second Quarter 2021 Financial Results
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial ...
A Preview Of Intersect ENT's Earnings
Intersect ENT (NASDAQ:XENT) announces its next round of earnings this Friday, August 06. Here is Benzinga's everything-that-matters guide for this Friday's Q2 earnings announcement.
Intersect ENT (XENT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System High...
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S....
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
Intersect ENT Inc (NASDAQ: XENT) expects Q2 sales of approximately $27.3 million, slightly below the consensus estimate of $28.02 million. Record quarterly revenue from the Sinuva sinus implant is appro...
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
Intersect ENT (XENT) Surges 5.2%: Is This an Indication of Further Gains?
Intersect ENT (XENT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase i...